Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:AMARNASDAQ:ANCNNASDAQ:EVOKOTCMKTS:ICOTF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.60$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsANCNAnchiano Therapeutics$0.78+1.3%$21.77$0.51▼$10.55$5.78M0.933.15 million shs28,500 shsEVOKEvoke Pharma$0.61+3.4%$0.66$0.56▼$2.42$5.17M0.2163,715 shs30,344 shsICOTFiCo Therapeutics$0.37+5.6%$0.37$0.80▼$1.82$3.39M2.034,760 shs2,600 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%ANCNAnchiano Therapeutics+4.01%-1.25%+16.27%+46.98%-51.61%EVOKEvoke Pharma+0.83%+3.39%-3.28%-41.92%-69.65%ICOTFiCo Therapeutics+2.70%-2.24%-28.40%+8.83%+8.83%[BUY ALERT] Our #1 A.I. Stock for March (Ad)It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo BiosciencesN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00ANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/AEVOKEvoke Pharma$5.18M1.00N/AN/A($0.77) per share-0.79ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/AANCNAnchiano Therapeutics-$27.12M-$3.465.19N/AN/AN/A36.08%27.40%N/AEVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)ICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ALatest ICOTF, ANCN, AMAR, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07ANCNAnchiano TherapeuticsN/A3.253.25EVOKEvoke Pharma9.292.252.09ICOTFiCo TherapeuticsN/A0.720.72OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/AANCNAnchiano Therapeutics9.05%EVOKEvoke PharmaN/AICOTFiCo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%ANCNAnchiano Therapeutics6.88%EVOKEvoke Pharma11.78%ICOTFiCo TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableICOTF, ANCN, AMAR, and EVOK HeadlinesSourceHeadlineProtein therapeutics: a summary and pharmacological classificationnature.com - February 19 at 10:26 PM10 Best ICO Crypto Tokens to Watch & Invest in January 2024techreport.com - January 31 at 12:39 PMICO issues guidance on workplace surveillancecomputerweekly.com - October 8 at 7:53 AMJervois waiting for better days at ICOminingweekly.com - August 12 at 2:33 AMICO Group Ltd.wsj.com - May 10 at 8:20 AMUK data regulator fines TikTok £13M for letting children under 13 on platformpolitico.eu - April 11 at 9:54 AMAntisense & RNAi Therapeutics Market 2023 Estimated to Perceive Exponential Growth till 2028marketwatch.com - February 25 at 5:28 PM5 Upcoming ICO of February 2023hindustantimes.com - February 23 at 4:50 PMWomen's health therapeutics market size to increase by USD 30.35 billion: North America to account for 37% of market growth - Technaviofinance.yahoo.com - February 19 at 12:00 AMJasper Therapeutics releases promising early-stage data on sickle cell disease treatmentseekingalpha.com - February 19 at 12:00 AMFirms urged to check own data protection rules by ICOthetelegraphandargus.co.uk - January 25 at 1:50 PMICO selectively discloses reprimands for data protection breachescomputerweekly.com - October 14 at 12:32 AMConsumers to Ditch Cafes for Coffee at Home Amid Rising Prices, Says ICOusnews.com - October 10 at 12:40 AMSatellos Bioscience Inc (MSCL)investing.com - August 16 at 7:49 PMSatellos Bioscience GAAP EPS of -C$0.06seekingalpha.com - June 1 at 4:16 PMSatellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophiesfinance.yahoo.com - December 16 at 7:53 AMSatellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16thfinance.yahoo.com - December 15 at 6:51 AMICOTF: Targeting Stem Cells for Muscular Dystrophy Treatmentfinance.yahoo.com - December 9 at 2:33 PMSatellos Bioscience Announces New Board Appointmentsfinance.yahoo.com - December 6 at 7:39 AMiCo Therapeutics Inc (MSCL)investing.com - December 2 at 8:47 PMSatellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlightsfinance.yahoo.com - November 29 at 1:29 PMSatellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Servicesfinance.yahoo.com - October 27 at 9:08 AMiCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.finance.yahoo.com - August 5 at 5:57 PMNew MarketBeat Followers Over TimeCompany DescriptionsAmarillo BiosciencesOTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Anchiano TherapeuticsNASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.iCo TherapeuticsOTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.